Evidence map›Paper›PMID 33980601›Full record

ArticleJournal of virology2021

Host-Virus Chimeric Events in SARS-CoV-2-Infected Cells Are Infrequent and Artifactual.

Bingyu Yan, Srishti Chakravorty, Carmen Mirabelli, Luopin Wang, Jorge L Trujillo-Ochoa, Daniel Chauss, Dhaneshwar Kumar, Michail S Lionakis, Matthew R Olson, Christiane E Wobus and 2 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Safety concern of recombination between self-amplifying mRNA vaccines and viruses is mitigated in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Bingyu Yan *Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.
Srishti Chakravorty *Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.
Carmen Mirabelli *Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Luopin WangDepartment of Computer Science, Purdue University, West Lafayette, Indiana, USA.
Jorge L Trujillo-OchoaImmunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.
Daniel ChaussImmunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.
Dhaneshwar KumarDepartment of Biochemistry, Purdue University, West Lafayette, Indiana, USA.
Michail S LionakisFungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
Matthew R OlsonDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
Christiane E Wobus *Department of Microbiology and Immunology, University of Michigan, Ann Arbor, Michigan, USA.
Behdad Afzali *Immunoregulation Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, Maryland, USA.
Majid Kazemian *Department of Biochemistry, Purdue University, West Lafayette, Indiana, USA.
Purdue University West Lafayette · USNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity of Michigan · USNational Institute of Allergy and Infectious Diseases · US

Funding

Michigan Institute for Clinical and Health Research (MICHR)UL1TR002240 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LUMENG, JULIE C, MASHOUR, GEORGE ALEXANDER · 2017 to 2022
$54.9M
Immunopathogenesis of Fungal InfectionsZIAAI001175 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LIONAKIS, MICHAIL · 2012 to 2025
$23.9M
Unravelling immunoregulatory circuits of tissue inflammationZIADK075149 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI AFZALI, BEHDAD · 2019 to 2025
$19.3M
Joint submission for administrative supplement proposal: HIPAA aligned storage and computing solutionR35GM138283 · NIGMS · PURDUE UNIVERSITY · PI KAZEMIAN, MAJID · 2020 to 2024
$2.0M
The pathogenesis of COVID-19ZIAAI001318 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LIONAKIS, MICHAIL · 2020 to 2023
$290k
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) ZIA/AI001175HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ZIA/DK075149HHS | NIH | National Institute of General Medical Sciences (NIGMS) R35GM138283Intramural NIH HHS ZIA AI001175Intramural NIH HHS ZIA DK075149Marie Skłodowska-Curie Actions Individual Fellowship 841247MICHR Postdoc Translational Scholar Program UL1TR002240NCATS NIH HHS UL1 TR002240NIGMS NIH HHS R35 GM138283Office of Dietary Supplements (ODS)
6 · The paper itself

Abstract

The pathogenic mechanisms underlying severe SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection remain largely unelucidated. High-throughput sequencing technologies that capture genome and transcriptome information are key approaches to gain detailed mechanistic insights from infected cells. These techniques readily detect both pathogen- and host-derived sequences, providing a means of studying host-pathogen interactions. Recent studies have reported the presence of host-virus chimeric (HVC) RNA in transcriptome sequencing (RNA-seq) data from SARS-CoV-2-infected cells and interpreted these findings as evidence of viral integration in the human genome as a potential pathogenic mechanism. Since SARS-CoV-2 is a positive-sense RNA virus that replicates in the cytoplasm, it does not have a nuclear phase in its life cycle. Thus, it is biologically unlikely to be in a location where splicing events could result in genome integration. Therefore, we investigated the biological authenticity of HVC events. In contrast to true biological events like mRNA splicing and genome rearrangement events, which generate reproducible chimeric sequencing fragments across different biological isolates, we found that HVC events across >100 RNA-seq libraries from patients with coronavirus disease 2019 (COVID-19) and infected cell lines were highly irreproducible. RNA-seq library preparation is inherently error prone due to random template switching during reverse transcription of RNA to cDNA. By counting chimeric events observed when constructing an RNA-seq library from human RNA and spiked-in RNA from an unrelated species, such as the fruit fly, we estimated that ∼1% of RNA-seq reads are artifactually chimeric. In SARS-CoV-2 RNA-seq, we found that the frequency of HVC events was, in fact, not greater than this background "noise." Finally, we developed a novel experimental approach to enrich SARS-CoV-2 sequences from bulk RNA of infected cells. This method enriched viral sequences but did not enrich HVC events, suggesting that the majority of HVC events are, in all likelihood, artifacts of library construction. In conclusion, our findings indicate that HVC events observed in RNA-sequencing libraries from SARS-CoV-2-infected cells are extremely rare and are likely artifacts arising from random template switching of reverse transcriptase and/or sequence alignment errors. Therefore, the observed HVC events do not support SARS-CoV-2 fusion to cellular genes and/or integration into human genomes.

Indexed as

Host-Pathogen InteractionsRNA-SeqVirus ReplicationCell Line, TumorCOVID-19HumansRNA, ViralSARS-CoV-2RNA, Viralchimeric readsCOVID-19host-virus fusionRNA sequencingSARS-CoV-2sequencing reads

Identifiers

PMID33980601
PMCPMC8274596
OpenAlexW3163570583

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.